ReviewFrontiers in molecular neuroscience2015
MAG, myelin and overcoming growth inhibition in the CNS.
Review in Frontiers in molecular neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 97 citations in OpenAlex.
- Insights from TPPP3 and its family member proteins in neuronal diseases.Neural regeneration research · 2026Article
- Article
- Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration.Acta neuropsychiatrica · 2026Review
- Siglecs: From Biomodulation to Immunotherapy.Current protein & peptide science · 2026Review
- Poly-L-Ornithine coated plant scaffolds support motor recovery in rats after traumatic spinal cord injury.Scientific reports · 2025Article
- IGFBP2-Ceramide Pathway Mediates Divergent Myelin Breakdown in the PNS and CNS Following Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- How Growth Cones Sense Extracellular Cues and Drive Neuronal Migration: Shared Mechanisms Between Growth Cones of Migrating Neurons and Axons.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025Review
- Unraveling the role of MAG, PTEN, and NOTCH1 in axonal regeneration: a network analysis and molecular dynamics study of siRNA/drugs/nanocarriers interactions.Journal of translational medicine · 2025Article
- Review
- Cellular crosstalk in organotypic vasculature: mechanisms of diabetic cardiorenal complications and SGLT2i responses.Cardiovascular diabetology · 2025Article
- Alcohol induces concentration-dependent transcriptomic changes in oligodendrocytes.Addiction biology · 2025Article
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Spinal Cord Injury.Molecular neurobiology · 2025Review
- Unveiling the Role of Schwann Cell Plasticity in the Pathogenesis of Diabetic Peripheral Neuropathy.International journal of molecular sciences · 2024Review
- A NovelGenes · 2024Article
- The role of foam cells in spinal cord injury: challenges and opportunities for intervention.Frontiers in immunology · 2024Review
- Spinal cord injury: pathophysiology, possible treatments and the role of the gut microbiota.Frontiers in microbiology · 2024Review
- Regulation of axonal regeneration after mammalian spinal cord injury.Nature reviews. Molecular cell biology · 2023Review
- Polymeric Based Hydrogel Membranes for Biomedical Applications.Membranes · 2023Review
- Current Advancements in Spinal Cord Injury Research-Glial Scar Formation and Neural Regeneration.Cells · 2023Review
- Axonal Regeneration: Underlying Molecular Mechanisms and Potential Therapeutic Targets.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While neurons in the central nervous system (CNS) have the capacity to regenerate their axons after injury, they fail to do so, in part because regeneration is limited by growth inhibitory proteins present in CNS myelin. Myelin-associated glycoprotein (MAG) was the first myelin-derived growth inhibitory protein identified, and its inhibitory activity was initially elucidated in 1994 independently by the Filbin lab and the McKerracher lab using cell-based and biochemical techniques, respectively. Since that time we have gained a wealth of knowledge concerning the numerous growth inhibitory proteins that are present in myelin, and we also have dissected many of the neuronal signaling pathways that act as stop signs for axon regeneration. Here we give an overview of the early research efforts that led to the identification of myelin-derived growth inhibitory proteins, and the importance of this family of proteins for understanding neurotrauma and CNS diseases. We further provide an update on how this knowledge has been translated towards current clinical studies in regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.